Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ADC TherapeuticsADCT -2.73%41 12-1 Month Momentum % is -56.88% as of Aug. 06, 2026. GuruFocus rates ADCT with a GF Score™ of 41/100 and a GF Value™ of $2.08 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,014 Drug Manufacturers companies, ADC Therapeutics ranks worse than 93.29% on this metric.
12-1 Month Momentum % is the total return of the stock from 12-month ago to 1-month ago. As of today (2026-08-06), ADC Therapeutics's 12-1 Month Momentum % is -56.88%.
The industry rank for ADC Therapeutics's 12-1 Month Momentum % or its related term are showing as below:
ADCT's 12-1 Month Momentum % is ranked worse than 93.29% of 1014
companies
in the Drug Manufacturers industry
Industry Median: -13.29
vs ADCT: -56.88
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 12-1 Month Momentum % measures the total return to a stock over the past twelve months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
ADC Therapeutics 12-1 Month Momentum % Related Terms
ADCT vs LFCR, DERM, BGM: 12-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, ADC Therapeutics's 12-1 Month Momentum %, along with its competitors' market caps and 12-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADC Therapeutics 12-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, ADC Therapeutics's 12-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where ADC Therapeutics's 12-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a 12-1 Month Momentum % of -56.88% mean?
ADC Therapeutics (ADCT) has a 12-1 Month Momentum % of -56.88% as of Aug. 06, 2026. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on ADC Therapeutics and its competitors. According to the industry distribution chart, ADC Therapeutics ranks #946 out of 1014 companies in the Drug Manufacturers industry, placing it in the top 93.3%.
Is ADC Therapeutics' 12-1 Month Momentum % too high?
ADC Therapeutics' current 12-1 Month Momentum % is -56.88%. Based on the distribution chart, ADC Therapeutics ranks #946 out of 1014 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, ADC Therapeutics has a GF Score™ of 41/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does ADC Therapeutics' 12-1 Month Momentum % compare to LFCR and DERM?
According to the Drug Manufacturers industry distribution chart, ADC Therapeutics ranks #946 out of 1014 companies for 12-1 Month Momentum %. This places ADC Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 12-1 Month Momentum % for a Drug Manufacturers company?
A good 12-1 Month Momentum % depends on the Drug Manufacturers industry context. However, 12-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 12-1 Month Momentum % mean?
A high 12-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 12-1 Month Momentum measures the total return of the stock from 12-month ago to 1-month ago. View historical data on ADC Therapeutics and its competitors. ADC Therapeutics's current 12-1 Month Momentum % is -56.88%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADC Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, ADC Therapeutics (ADCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.08, compared to a current price of $1.07 — trading 48.6% below its estimated fair value. The current 12-1 Month Momentum % is -56.88%. ADC Therapeutics' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 12-1 Month Momentum % calculated?
12-1 Month Momentum % is calculated from a company's financial statements. For ADC Therapeutics (ADCT), the current 12-1 Month Momentum % is -56.88% as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ADC Therapeutics (ADCT) Overvalued in 2026?
Based on GuruFocus' analysis, ADC Therapeutics stock appears to be undervalued.
The current stock price of $1.07 is trading 48.6% below its estimated GF Value™ of $2.08.
GuruFocus considers ADC Therapeutics to be Possible Value Trap.
Key valuation signals for ADCT:
12-1 Month Momentum %: -56.88%
GF Value™: $2.08 vs. price of $1.07 (48.6% below fair value)
No single metric tells the full story. See the ADCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
41GF Score
Get the complete analysis for ADCT
12-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ADCT has been successfully added to your 
